Through a partnership between Novo Nordisk and the University of Oxford, we are now seeking highly motivated individuals to join our lab as postdoctoral research fellows. We have two 3-year fellowships available:
Comprehensive proteomic profiling of vesicle-mediated glucose transporter trafficking in human cells
Structural and functional exploration of GTPase-mediated glucose transporter trafficking
Click here for further details including how to apply
A collaborative partnership between the Huber Lab, Myeloma UK and the Joyce and Norman Freed Foundation support our research efforts in improving treatment and finding a cure for multiple myeloma. The Freed Foundation recently met with our research team at the Structural Genomics Consortium to hear about the project and its latest progress.
Alison Goldberg said: “Having supported Myeloma UK over many years, my sister Sara and I have been impressed with the impact Myeloma UK and its work has had on myeloma patients. We wanted to visit the SGC and to understand the role they play. We were so impressed with the facilities at the SGC as well as the excellent progress being made with the research. Results from this study will help to optimise the use of current and future treatments. It’s really encouraging to see the impact our funding is having on research.”
What makes a good drug target? Technology Networks has recently featured an article highlighting some of the challenges that the Huber Lab aims to tackle.
Dr Kilian V. M. Huber states,"A good drug target needs to be relevant to the disease phenotype and should be amenable to therapeutic modulation. At the same time, you need to have a good therapeutic window to assure that any therapeutic modality aimed at the target will not cause side effects by disrupting the physiological function of the target in healthy tissue."